For Institutions
About
Truist Securities raises Albemarle's price target to $125 from $91, citing lithium market momentum. Albemarle shares rise 4.2% premarket to $136.30 as lithium prices surge after China revokes mining licenses. Truist expects improved earnings and margins for Albemarle's energy storage business due to strong lithium demand. Currently, 9 out of 27 brokerages rate the stock as 'buy' or higher, with a median price target of $113. Albemarle shares are up 52.3% year-to-date.
Shares of lithium miners rise as lithium prices surge in China after the revocation of 27 mining licenses in Yichun. The most-active lithium carbonate contract on the Guangzhou Futures Exchange reached its highest since June 2024, closing up 7.61%. Albemarle rose 5%, SQM gained 7%, Sigma Lithium increased 13.5%, Lithium Americas up 3%, and Standard Lithium gained 3.7%.
Standard Lithium Ltd. reported a comprehensive loss of $3.998 million for the six months ended June 30, 2025, a stark contrast to a comprehensive income of $128.286 million in the same period last year. The basic loss per share was $0.03, with 196.603 million shares outstanding. The company continues to focus on lithium brine property exploration and maintains investments in joint ventures for exploration activities.
Standard Lithium(SLI) fell 20.22%, with a trading turnover 187.9 Million USD, and a year-to-date rose 194.5%. Omeros(OMER) fell 17.55%, with a trading turnover 62.4 Million USD, and a year-to-date fell 18%. Hims & Hers Health(HIMS) fell 15.84%, with a trading turnover 3.8 Billion USD, and a year-to-date rose 105.9%.
BofA has raised its price target for Albemarle to $118 from $110, citing a potential lithium market deficit next year due to production discipline and increased demand for Energy Storage Systems. Despite the limited upside, BofA maintains a Neutral rating on Albemarle. The brokerage notes that higher market prices could boost Albemarle's capex and volume growth, though caution is expected in the near term. Currently, 8 out of 27 brokerages rate the stock as "buy" or higher, with a median price target of $100.
